{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:53:01Z","timestamp":1772754781495,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10620-024-08630-3","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:02:36Z","timestamp":1725897756000},"page":"3911-3919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib"],"prefix":"10.1007","volume":"69","author":[{"given":"Tarek","family":"Odah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Karime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Picco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami A.","family":"Kinnucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"8630_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MOG.0000000000000740","volume":"37","author":"NA Cohen","year":"2021","unstructured":"Cohen NA, Rubin DT. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021;37:357\u2013363.","journal-title":"Curr Opin Gastroenterol."},{"key":"8630_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/ibd\/izab190","volume":"27","author":"Y Li","year":"2021","unstructured":"Li Y, Chen J, Bolinger AA et al. Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27:S38-s62.","journal-title":"Inflamm Bowel Dis."},{"key":"8630_CR3","doi-asserted-by":"publisher","first-page":"e21154","DOI":"10.1016\/j.heliyon.2023.e21154","volume":"9","author":"MH Derakhshan Nazari","year":"2023","unstructured":"Derakhshan Nazari MH, Shahrokh S, Ghanbari-Maman L et al. Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: a prospective study. Heliyon. 2023;9:e21154.","journal-title":"Heliyon."},{"key":"8630_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/14712598.2016.1203897","volume":"16","author":"L Pouillon","year":"2016","unstructured":"Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277\u20131290.","journal-title":"Expert Opin Biol Ther."},{"key":"8630_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"A Salas","year":"2020","unstructured":"Salas A, Hernandez-Rocha C, Duijvestein M et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:323\u2013337.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"8630_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","volume":"83","author":"P N\u00fa\u00f1ez","year":"2023","unstructured":"N\u00fa\u00f1ez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83:299\u2013314.","journal-title":"Drugs."},{"key":"8630_CR7","doi-asserted-by":"crossref","unstructured":"Rogler G. Efficacy of JAK inhibitors in Crohn's disease. J Crohns Colitis. 2020;14:S746\u2013s754.","DOI":"10.1093\/ecco-jcc\/jjz186"},{"key":"8630_CR8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s10620-022-07444-5.","volume":"67","author":"SD Lee","year":"2022","unstructured":"Lee SD, Singla A, Harper J et al. Tofacitinib appears well tolerated and effective for the treatment of patients with refractory Crohn\u2019s disease. Dig Dis Sci. 2022;67:4043\u20134048. https:\/\/doi.org\/10.1007\/s10620-022-07444-5.","journal-title":"Dig Dis Sci."},{"key":"8630_CR9","doi-asserted-by":"crossref","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical guideline: Ulcerative colitis in adults. Official jornal of the American College of Gastroenterology ACG. 2019;114:384\u2013413.","DOI":"10.14309\/ajg.0000000000000152"},{"key":"8630_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161\u2013170.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"8630_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T et al. Upadacitinib Is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023;21:1913-1923.e1912.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8630_CR12","doi-asserted-by":"crossref","unstructured":"Levine J, McKibbin J, Ham R, et al. Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative colitis patients: a single-center case 2series. Inflamm Bowel Dis. 2023.","DOI":"10.1093\/ibd\/izad279"},{"key":"8630_CR13","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","volume":"21","author":"L Boneschansker","year":"2023","unstructured":"Boneschansker L, Ananthakrishnan AN. Comparative effectiveness of Upadacitinib and Tofacitinib in inducing remission in Ulcerative colitis: real-world data. Clin Gastroenterol Hepatol. 2023;21:2427-2429.e2421.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8630_CR14","doi-asserted-by":"crossref","unstructured":"Radcliffe M, Long MD, Barnes EV, et al. Efficacy of Upadacitinib in patients previously treated with tofacitinib for the management of ulcerative colitis. Inflammatory Bowel Diseases. 2023.","DOI":"10.1093\/ibd\/izac247.157"},{"key":"8630_CR15","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e2114.","journal-title":"Gastroenterology."},{"key":"8630_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128.","journal-title":"Lancet."},{"key":"8630_CR17","doi-asserted-by":"publisher","first-page":"175628482311582","DOI":"10.1177\/17562848231158235","volume":"16","author":"K Ernest-Suarez","year":"2023","unstructured":"Ernest-Suarez K, Panaccione R. Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. Ther Adv Gastroenterol. 2023;16:17562848231158236.","journal-title":"Ther Adv Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08630-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:07:04Z","timestamp":1729274824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8630"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08630-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tarek Odah, Christian Karime, Aakash Desai, Michael Picco and Jana G. Hashash: N\/A. Jami Kinnucan: Consultant of AbbVie, BMS, Fresenius Kabi, Janssen, Pfizer and Takeda. Francis Farraye: Consultant of AbbVie, Avalo Therapeutics, BMS, Braintree Labs, Fresenius Kabi, GSK, Iterative Health, Janssen, Pfizer, Pharmacosmos, Sandoz Immunology, Sebela and Viatris. He is an independent contractor for GI Reviewers and IBD Educational Group. He sits on a DSMB for Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval was obtained to collect de-identified patient information through retrospective chart review at a large multicenter academic medical system in the United States.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}